Monoamine oxidase (EC 1.4.3.4) exists in at least two forms (termed type A and type B) with different substrate and inhibitor specificities (Johnston, 1968; Knoll & Magyar, 1972) . Amine neurotransmitters are among a wide range of substrates (Blaschko, 1974) and abnormalities of monoamine oxidase activity may therefore contribute to neurological disease. Most studies of such diseases have looked at monoamine oxidase activity in platelets (see Sandler et al., 198 l) , where only B-type activity is found (Donnelly & Murphy, 1977) . In contrast, neurological tissue in many mammals has been reported to contain both A-and B-type activities (see Achee et al., 1977) . Type A monoamine oxidase is sensitive to clorgyline at ~O-'M (Johnston, 1968) while type B is inhibited by 10-6M-deprenyl (Knoll & Magyar, 1972) . Both of these inhibitors bind irreversibly into the active site of the enzyme molecule and compete with the substrate and with a third inhibitor, pargyline. A-and B-type activity can therefore be blocked selectively by preincubation with the appropriate inhibitor. 3H-labelled pargyline also binds irreversibly to the active site and can therefore be used to estimate the number of active sites or to follow the presence of the subunit containing the active site after gel electrophoresis. We have employed these approaches to investigate the nature of the monoamine oxidase activity found in human brain and compared it with the A-type activity of human placental mitochondria and with the B-type activity of human platelets.
Mitochondria were prepared from human autopsy brain (temporal cortex) or fresh placenta (as described by Brown et al., 1980). Platelets were obtained from human blood (Brown et al., 1980) . Assay of monoamine oxidase activity was performed using 13Hltryptamine as substrate and the number of active sites was estimated by incubating with 1.33 x 10-6~-[3Hlpargyline (Summers et al., 1982) .
Preincubation with M-deprenyl totally inhibits platelet monoamine oxidase activity and abolishes the specific binding of I 'Hlpargyline to active sites. This concentration of deprenyl has no effect on the activity or the pargyline binding of placental (A-type) enzyme. Studies on brain mitochondria with selective inhibitors indicated that about 60% of the activity is resistant to clorgyline (lo-' M) but sensitive to deprenyl ( M) and presumably therefore represents type A enzyme. However, binding assays with [ 3H]pargyline employing similar inhibitors and concentrations revealed that most (>90%) of the monoamine oxidase molecules in the brain preparation were of type B. Thus the molecular turnover numbers for the two enzyme forms are quite different in this tissue. The turnover number calculated for the type B enzyme in brain (15 molecules/min) is very similar to the average value of 12 obtained with human platelets and is subject to the same limitations in estimation (Summers et al., 1982) . The type A enzyme from brain had a molecular turnover number of about 300, which is comparable with a value . Thus the relatively low proportion of monoamine oxidase type A molecules in the brain mitochondria contribute substantially to the total brain activity. The apparent molecular weights of the A-and B-type monoamine oxidases of brain were examined by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis after preincubation with clorglyline or deprenyl and labelling with [ 3H1pargyline (Cawthon & Breakefield, 1979; Brown et al., 1980) . Without preincubation, most of the brain enzyme ran as a band migrating with an apparent Mr of about 58000 (see Fig. 1 ). This is smaller than the apparent Mr of the placental enzyme (65000) determined on the same gel and corresponds with the single band observed for platelets and the main band from liver mitochondria (Craig et al., 198 1). After preincubation with 10-7~-clorgyEne this band was still present, but it was not evident when the brain mitochondria were preincubated with M-deprenyl, indicating that it consists of B-type molecules. However, aRer prolonged exposure of the fluorograph, a faint band migrating in the same position as the placental band could be seen in the deprenyl-treated sample. Thus the small number of A-type molecules in the brain mitochondria have the same apparent Mr as the A-type monoamine oxidase of placenta. Analysis of partial proteolytic digestion products of the labelled brain enzyme confirmed the observation that the predominant form is type B and similar to that observed in platelets. , 1980) . The unusual form of creatine kinase in serum has been identified with mitochondrial creatine kinase because of the similarity of its electrophoretic mobility to that of creatine kinase extracted from mitochondria of human heart (Wevers et al., 1980) or brain (Lindsey & Diamond, 1978) . Also, authentic mitochondrial creatine kinase, like the isoenzyme in serum, is not inhibited by antibody to creatine kinase M subunits. We now report the occurrence of creatine kinase of apparent mitochondrial origin in the serum of a 15-day-old boy who had myocarditis with congestive cardiac failure due to infection with Coxsackie virus. Total creatine kinase, measured at 37OC by the Scandinavian recommended method (Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology, 1979) , was 1098 unitsh, of which 569 units/l remained after immunoinhibition with antibody to M subunits (Gerhardt et al., 1977) . Electrophoresis on cellulose acetate in barbitone buffer (0.03 mol/l; pH 8.6) with 5 mmol/lN-acetylcysteine followed by incubation with complete creatine kinase reaction mixture and fluorescence scanning showed a strong zone of MM isoenzyme, a faint zone of MB creatine kinase and two zones (one strong and one faint) to the cathode side of the MM isoenzyme (Fig. 1) . The absence of fluorescence on incubation without creatine phosphate indicates that all these zones were indeed creatine kinase. Incubation in the presence of antibody inhibitory to M subunits abolished the MM zone and diminished the zone of MB creatine kinase, whereas the two bands to the cathode side of MM creatine kinase were unaffected (Fig. 1) .
On gel filtration (Sepharose 6B or Sephadex G-200) the main 'mitochondrial' creatine kinase activity eluted in the same position as MM and MB creatine kinases. Mitochondria1 and cytoplasmic creatine kinase isoenzymes from animal species have also been shown to have similar molecular weights (Hall et al., 1979; Roberts & Grace, 1980) . . m e electrophoretic mobility and size of the presumed mitochondrial isoenzyme in the serum of our patient distinguished it from the variants occasionally found in serum that appear to be due to association of MM or BB creatine kinases with immunoglobulins (Kwong & Arvan, 198 1).
The presumed mitochondrial creatine kinase had disappeared from the child's serum 5 days after the first observation, when he had largely recovered from his illness. Electrophoresis showed KATHERINE A. HALLIDIE-SMITH mainly the MM isoenzyme together with small amounts of MB and BB creatine kinases.
The presumed tissue source of the mitochondrial creatine kinase in our patient's serum was the myocardium. However, other possible sources cannot be entirely ruled out. Earlier reports have shown little correlation between the presence of mitochondrial creatine kinase and the total activity of the enzyme in serum (James & Harrison, 1979) , or between the presence and relative activities of mitochondrial and MB isoenzymes (Bark, 1980) . If mitochondrial creatine kinase is a distinct isoenzyme determined by a separate gene locus, as the structural differences between cytoplasmic and mitochondrial creatine kinases from animal tissues seem to suggest (Roberts & Grace, 1980) , there is no reason why the tissue distributions of the cytoplasmic and mitochondrial isoenzymes should be identical. Therefore, release of mitochondrial creatine kinase may result from damage to tissues other than those with a high content of the cytoplasmic isoenzymes. However, such studies 
